Isomorphic Labs raises $5B for AI drug trials
isomorphic labs raised $5 billion to take its ai-designed drug candidates to clinical trials, advancing its work in oncology and immunology.
isomorphic labs, an ai drug-discovery platform spun out of google's deepmind in 2021, raised $5 billion in series c funding. the funding was co-led by greenoaks and sequoia capital, with participation from andreessen horowitz and existing backers including alphabet's venture divisions gv and capital g. isomorphic labs uses ai models, building on deepmind's alphafold protein-folding ai model, to design drugs. the company has struck deals with pharma giants like eli lilly, novartis, and johnson & johnson, and will use the funding to continue developing its drug-design engine and expand into more types of medicine.